Meningococcal groups C and Y and haemophilus B tetanus toxoid conjugate vaccine (HibMenCY-TT; MenHibrix(®)): a review (Q38104685)

28 August 2017

Meningococcal groups C and Y and haemophilus B tetanus toxoid conjugate vaccine (HibMenCY-TT; MenHibrix(®)): a review (English)

1 reference

28 August 2017

1 reference

1

Caroline M Perry

1 reference

28 August 2017

language of work or name

1 reference

1 May 2013

1 reference

28 August 2017

1 reference

28 August 2017

73

1 reference

28 August 2017

7

1 reference

28 August 2017

703-713

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-013-0048-9

28 August 2017

0 references

cites work

A review of vaccine research and development: meningococcal disease

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0048-9

Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0048-9

Meningococcal disease: the organism, clinical presentation, and worldwide epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0048-9

Update on meningococcal disease with emphasis on pathogenesis and clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0048-9

Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0048-9

The epidemiology of meningococcal disease and the impact of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0048-9

Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0048-9

The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0048-9

Epidemiological profile of meningococcal disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0048-9

The epidemiology of pneumococcal, meningococcal, and Haemophilus disease in the Middle East and North Africa (MENA) region--current status and needs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0048-9

Global epidemiology of meningococcal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0048-9

Prospects for vaccine prevention of meningococcal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0048-9

Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0048-9

Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0048-9

Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0048-9

Human immunity to the meningococcus. I. The role of humoral antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0048-9

A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0048-9

Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: a pooled analysi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0048-9

Public health and economic benefits of new pediatric influenza vaccination programs in Argentina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0048-9

Antibody persistence for up to 5 years after a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) given at 12-15 months of age

21 January 2018

1 reference

12 December 2020

Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the Unit

1 reference

12 December 2020

Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland

1 reference

12 December 2020

The safety profile of Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY)

1 reference

12 December 2020

Updated recommendations for use of meningococcal conjugate vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010.

1 reference

12 December 2020

Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine

1 reference

12 December 2020

The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b

1 reference

12 December 2020

The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b

1 reference

12 December 2020

Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine

1 reference

12 December 2020

Immunogenicity and safety of an investigational combined haemophilus influenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine

1 reference

12 December 2020

Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies

1 reference

12 December 2020

Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule

1 reference

12 December 2020

Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience

1 reference

12 December 2020

Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale.

1 reference

12 December 2020

Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants

1 reference

12 December 2020

Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of age

1 reference

12 December 2020

10.1007/S40265-013-0048-9

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1016179496

0 references

Fatcat ID

release_suvefw2wlzg6bc63gdsji5y66m

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/suvefw2wlzg6bc63gdsji5y66m

24 November 2022

mapped directly with Wikidata item

1 reference